SCHEMBL19255842

SCHEMBL19255842

Cc1ccc(S(=O)(=O)N(C)C)cc1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
HTR2C P28335 2/20 0.53
HTR2A P28223 1/20 0.53
ALDH1A1 P00352 9/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
THRB P10828 1/20 0.49
GAA P10253 1/20 0.48
RAB9A P51151 1/20 0.48
PKM P14618 3/20 0.47
HTR2B P41595 1/20 0.47
VCAM1 P19320 1/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47
PDE2A O00408 1/20 0.47
PDE5A O76074 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6265475 0.82 ALDH1A1 (0.56) LMNATDP1HTR2CALDH1A1HTT
SCHEMBL172720 0.82 ESR1 (0.56) LMNAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL5623940 0.82 ALDH1A1 (0.60) LMNATDP1HTR2CALDH1A1HTT
SCHEMBL711751 0.82 MAPT (0.62) LMNAHTR2CALDH1A1HTTSMN1; SMN2
SCHEMBL1369561 0.82 MAPT (0.57) LMNAHTR2CALDH1A1HTTSMN1; SMN2
SCHEMBL23057074 0.82 VCAM1 (0.60) LMNAHTR2CALDH1A1HTTSMN1; SMN2
SCHEMBL6262742 0.82 L3MBTL1 (0.54) LMNAHTR2CALDH1A1HTTSMN1; SMN2
SCHEMBL1460104 0.79 ALDH1A1 (0.43) LMNAHTR2CHTR2AALDH1A1HTT
SCHEMBL21101747 0.79 LMNA (0.50) LMNAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL12537974 0.79 ALDH1A1 (0.47) LMNAALDH1A1HTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
WO-2019111225-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS AVALIV THERAPEUTICS (US) 2019-06-13 WO disclosed
WO-2017136870-A9 HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-02-15 WO disclosed
WO-2017136870-A1 HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 LMNA 2513/4885TDP1 3260/4885HTR2C 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.